Showing 1171-1180 of 1378 results for "".
- Meeting Pearls and More: Don't Miss DermTube's Summer AAD Coveragehttps://practicaldermatology.com/news/dont-miss-dermtubes-summer-aad-coverage/2458481/Don’t Miss DermTube’s upcoming coverage of the Summer American Academy of Dermatology (AAD) Meeting in Boston. Summer AAD takes place from July 28-31, 2016. Hosted by Seemal R. Desai, MD
- Dermatologist Todd Schlesinger to Host Bellafill Discussion Fridayhttps://practicaldermatology.com/news/dermatologist-todd-schlesinger-to-host-bellafill-discussion-friday/2458484/Todd E. Schlesinger, MD, FAAD will host a program on behalf of Suneva, in which he will discuss Suneva's Bellafill® and other products. The event will be held Friday, July 29th, 2016 at 8pm at Towne Stove and Spirits, 900 Boylston Street, Boston. Those interested in atte
- Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Precisely to the Skinhttps://practicaldermatology.com/news/take-that-acne-bpx-01-topical-gel-delivers-minocycline-precisely-to-the-skin/2458490/BioPharmX Corporation’s novel topical minocycline, BPX-01, may be as effective as its oral counterpart minus the systemic side effects, new research suggests. "These results are promising, that topical minocycline gel delivered as BP
- Novan: First Patient Dosed in Phase 2 Anti-Fungal Programhttps://practicaldermatology.com/news/nolan-first-patient-dosed-in-phase-2-anti-fungal-program/2458492/The first patient has been dosed in Novan's clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (“T. rubrum”). Novan is developing
- CeraVe: Suncare Products Get Skin Cancer Foundation Seal of Recommendationhttps://practicaldermatology.com/news/cerave-suncare-products-get-skin-cancer-foundation-seal-of-recommendation/2458495/Two products from Valeant Consumer Healthcare's CeraVe skincare line have received The Skin Cancer Foundation (SCF) Seal of Recommendation for sunscreens. CeraVe® AM Facial Moisturizing Lotion with SPF 30 has earned the “Daily Use” Seal and CeraVe
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- FDA Clears Syneron Candela's UltraShape Power for Fat Destructionhttps://practicaldermatology.com/news/fda-clears-syneron-candelas-ultrashape-power-for-fat-destruction/2458499/The FDA cleared Syneron Medical Ltd.'s non-invasive fat destruction device, UltraShape Power. for non-invasive reduction of abdominal circumference via fat cell destruction. UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat, offering measurab
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),